Machine signal
Active cluster sell — 3 distinct insiders, $308K, window ends Sep 14, 2026.
Figures computed from official regulatory filings — .
Analysttarget 34.03 USD (+482%) · consensus 5/5 · 9 buy · 0 hold · 0 sell
Ownershipinsiders 1.24% · institutions 84.24% · short 16.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Corbus Pharmaceuticals Holdings, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
183 buys39 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Nicacio Leonardo Viana |
| Award |
| n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) |
| SEC |
| Nicacio Leonardo Viana | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Saxena Nishant C | Buy | $25K | conv 51 | SEC |
| Moran Sean F.track record | Sell | $121K | SEC |
| Cohen Yuvaltrack record | Sell | $171.4K | SEC |
| Jenkins John Kenneth | Sell | $38K | SEC |
| Altmeyer Anne | Sell | $19.1K | SEC |
| Kung Winston | Sell | $16K | Unusual size | SEC |
| Saxena Nishant C | Buy | $33K | conv 58First in 12mo | SEC |
| Saxena Nishant C | Buy | $68.2K | conv 53 | SEC |
| Saxena Nishant C | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Saxena Nishant C | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jenkins John Kenneth | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kung Winston | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pfeiffenberger Brent | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jenkins John Kenneth | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jacques Rachelle Suzanne | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Altmeyer Anne | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ben Yong | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kung Winston | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pfeiffenberger Brent | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jacques Rachelle Suzanne | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Altmeyer Anne | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ben Yong | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |